UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Nature (London), 2016-06, Vol.534 (7607), p.341-346

2016

Link zum Volltext

Verfügbarkeit prüfen

Applications and analysis of targeted genomic sequencing in cancer studies

Computational and structural biotechnology journal, 2019-01, Vol.17, p.1348-1359

2019

Link zum Volltext

Verfügbarkeit prüfen

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma

Leukemia, 2018-05, Vol.32 (5), p.1261-1265

2018

Link zum Volltext

Verfügbarkeit prüfen

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression

Blood, 2017-01, Vol.129 (2), p.199-208

2017

Link zum Volltext

Verfügbarkeit prüfen

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition

Cancer discovery, 2016-11, Vol.6 (11), p.1248-1257

2016

Link zum Volltext

Verfügbarkeit prüfen

Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations

Epigenetics, 2017-05, Vol.12 (5), p.370-377

2017

Link zum Volltext

Verfügbarkeit prüfen

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia

Frontiers in oncology, 2023-05, Vol.13, p.1150149-1150149

2023

Link zum Volltext

Verfügbarkeit prüfen

Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma

Leukemia, 2019-06, Vol.33 (6), p.1540-1540

2019

Link zum Volltext

Verfügbarkeit prüfen

CD25 Targeting Eliminates Regulatory T Cells and CD25+ Blasts in Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.6291-6292

2022

Link zum Volltext

Verfügbarkeit prüfen

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment

Leukemia, 2024-02, Vol.38 (2), p.398-402

2024

Link zum Volltext

Verfügbarkeit prüfen

Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine

Expert review of molecular diagnostics, 2016-10, Vol.16 (10), p.1093-1102

2016

Link zum Volltext

Verfügbarkeit prüfen

Precision medicine and lymphoma

Current opinion in hematology, 2018-07, Vol.25 (4), p.329-334

2018

Link zum Volltext

Verfügbarkeit prüfen

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Blood, 2019-11, Vol.134 (Supplement_1), p.5319-5319

2019

Link zum Volltext

Verfügbarkeit prüfen

Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma

Haematologica (Roma), 2020-06, Vol.105 (6), p.318

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma

Blood advances, 2022-02, Vol.6 (3), p.1025-1037

2022

Link zum Volltext

Verfügbarkeit prüfen

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma (vol 32, pg 1258, 2018)

Leukemia, 2019-06, Vol.33 (6), p.1540-1540

2019

Link zum Volltext

Verfügbarkeit prüfen

Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant

Haematologica (Roma), 2019-04, Vol.104 (4), p.e174

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB558: Single cell profiling of PBMCs reveals correlates of clinical response to glofitamab

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.LB558-LB558

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(29)
Dissertationen
(1)

Sprache

Englisch
(30)
Japanisch
(6)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Blood
(12)
Leukemia
(4)
Blood Advances
(2)
Haematologica
(2)
Cancer Discovery
(1)
Cancer Research
(1)
Clinical Medicine
(1)
Computational And Structural Biotechnology Journal
(1)
Current Opinion In Hematology
(1)
Epigenetics
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Applications and analysis of targeted genomic sequencing in cancer studies

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition

Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia

Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma

CD25 Targeting Eliminates Regulatory T Cells and CD25+ Blasts in Acute Myeloid Leukemia

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment

Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine

Precision medicine and lymphoma

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma

Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma (vol 32, pg 1258, 2018)

Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Abstract LB558: Single cell profiling of PBMCs reveals correlates of clinical response to glofitamab

Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse

Suchergebnisse filtern